Subsequently, several MTOR inhibitors have been evaluated for the treatment of various cancers in phase III clinical trials, including Non-Hodgkin lymphoma, neuroendocrine tumors, gastric cancer, sarcoma, hepatocellular carcinoma, breast cancer, and etc. [40]. Here, MTOR is linked to sarcoma.